| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/26/2004 | WO2004071416A2 Novel inhibitors of formation of advanced glycation endproducts (ages) |
| 08/26/2004 | WO2004071413A2 Method and composition for potentiating an opiate analgesic |
| 08/26/2004 | WO2004071406A2 Creatine ester anti-inflammatory compounds and formulations |
| 08/26/2004 | WO2004071404A2 Use of il-6 antagonists in combination with steroids to enhance apoptosis |
| 08/26/2004 | WO2004071403A2 Coated particles and pharmaceutical dosage forms |
| 08/26/2004 | WO2004071402A2 STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR |
| 08/26/2004 | WO2004071401A2 Hydroxamic acid derivatives as histone deacetylase inhibitors (hdca) |
| 08/26/2004 | WO2004071400A2 Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| 08/26/2004 | WO2004071399A2 Modulation of atp production or content in the hypothalamus |
| 08/26/2004 | WO2004071398A2 Pharmaceutical patch |
| 08/26/2004 | WO2004071397A2 Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| 08/26/2004 | WO2004071391A2 Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders |
| 08/26/2004 | WO2004071390A2 Piperazine-2-carboxamide derivatives |
| 08/26/2004 | WO2004071388A2 Medicinal compounds |
| 08/26/2004 | WO2004071385A2 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention |
| 08/26/2004 | WO2004071384A2 New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| 08/26/2004 | WO2004071383A2 New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action |
| 08/26/2004 | WO2004071381A2 Drugs containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds |
| 08/26/2004 | WO2004071380A2 Drugs containing substituted 2-aryl-aminoacetic acid compounds |
| 08/26/2004 | WO2004071271A2 Improving fetal physiology during maternal surgery or diagnosis |
| 08/26/2004 | WO2004071211A1 Methods and compositions utilizing astaxanthin |
| 08/26/2004 | WO2004071156A2 Use of edible acid in fast-dispersing pharmaceutical solid dosage forms |
| 08/26/2004 | WO2004071152A2 Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders |
| 08/26/2004 | WO2004063336A3 Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis |
| 08/26/2004 | WO2004060903A3 Aerosolizable pharmaceutical formulation for fungal infection therapy |
| 08/26/2004 | WO2004060487A3 Composition for the treatment of hiv or aids |
| 08/26/2004 | WO2004060288A3 Topical compositions having a natural ingredient and method of use |
| 08/26/2004 | WO2004058679A3 Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| 08/26/2004 | WO2004058303A3 Compositions of benzoquinolizine carboxylic acid antibiotic drugs |
| 08/26/2004 | WO2004058164A3 Asthma and allergic inflammation modulators |
| 08/26/2004 | WO2004056349A3 Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents |
| 08/26/2004 | WO2004055163A3 Substituted 1-benzoyl-3-cyano-pyrrolo[1,2-a]quinolines |
| 08/26/2004 | WO2004054572A3 Novel benzopyran analogs and their use for the treatment of glaucoma |
| 08/26/2004 | WO2004054542A3 Oral drug delivery system comprising high viscosity liquid carrier materials |
| 08/26/2004 | WO2004054501A3 Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| 08/26/2004 | WO2004054500A3 Preparation of submicron sized particles with polymorph control and new polymorph of itraconazole |
| 08/26/2004 | WO2004053069A3 PROTECTION OF STEM CELLS FROM CYTOTOXIC AGENTS BY MODULATION OF β-CATENIN SIGNALING PATHWAYS |
| 08/26/2004 | WO2004052345A8 Coating composition for taste masking coating and methods for their application and use |
| 08/26/2004 | WO2004052294A3 Compositions and methods related to lipid:emodin formulations |
| 08/26/2004 | WO2004052236A3 Methods and compositions for treatment of otitis media |
| 08/26/2004 | WO2004050715A3 Tough polymers |
| 08/26/2004 | WO2004048504A3 Method and composition with conjugated linoleic acid esters |
| 08/26/2004 | WO2004045611A8 Use of a thiazolidinedione for the reduction of side effects of chemotherapy |
| 08/26/2004 | WO2004045608A9 Pharmaceutical compositions containing a biguanide-glitazone combination |
| 08/26/2004 | WO2004045509A3 Method of using a cox-2 inhibitor and a 5-ht1a receptor modulator as a combination therapy |
| 08/26/2004 | WO2004045392A3 Diagnostic method for celiac sprue |
| 08/26/2004 | WO2004044163A9 Methods for identifying risk of melanoma and treatments thereof |
| 08/26/2004 | WO2004043434B1 Oral testosterone delivery system with improved sustained release |
| 08/26/2004 | WO2004043355A3 Alpha, alpha-disubstituted benzylglycine derivatives as hiv protease inhibitors |
| 08/26/2004 | WO2004043229A3 Compounds for the treatment of tobacco dependence and withdrawal |
| 08/26/2004 | WO2004041185A3 Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells |
| 08/26/2004 | WO2004039336A3 Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia |
| 08/26/2004 | WO2004037314A3 Patch and kit containing delayed-type hypersensitivity inducer |
| 08/26/2004 | WO2004037228A8 Sustained release compositions containing alfuzosin |
| 08/26/2004 | WO2004037212A3 Compositions comprising zopiclone derivatives and methods of making and using the same |
| 08/26/2004 | WO2004035523B1 Cationic cardiolipin analogs and use thereof |
| 08/26/2004 | WO2004035169A3 Multidimensional protein separation system |
| 08/26/2004 | WO2004035002A3 Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
| 08/26/2004 | WO2004034023A3 Methods of synthesizing 3-amino-1,2,4-benzotriazines |
| 08/26/2004 | WO2004032826A3 Process for preparing tannate tablet capsule or other solid dosage forms |
| 08/26/2004 | WO2004032824A3 Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
| 08/26/2004 | WO2004028589A3 Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device |
| 08/26/2004 | WO2004028548A3 Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents |
| 08/26/2004 | WO2004028465A3 Hemostatic compositions and methods |
| 08/26/2004 | WO2004026909A3 Method of treating rheumatoid arthritis by interfering with expression of dc-sign by macrophages and diagnosis thereof |
| 08/26/2004 | WO2004026261A3 Composition containing ribavirin and use thereof |
| 08/26/2004 | WO2004024897A3 PHENYL-AZA-BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| 08/26/2004 | WO2004023340A3 Non-psychotropic cannabinoids for prevention of cognitive impairment |
| 08/26/2004 | WO2004021990A3 Compositions and kits for the removal of irritating compounds from bodily surfaces |
| 08/26/2004 | WO2004021988A3 Treatment of pain by inhibition of p38 map kinase |
| 08/26/2004 | WO2004017922B1 Keto cannabinoids with therapeutic indications |
| 08/26/2004 | WO2004013310A3 Methods of down regulating target gene expression in vivo by introduction of interfering rna |
| 08/26/2004 | WO2004010936A3 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 08/26/2004 | WO2004006863A3 Therapeutic devices for patterned cell growth |
| 08/26/2004 | WO2004004686A3 Cartilage enhancing food supplements and methods of preparing the same |
| 08/26/2004 | WO2004004653A3 Methods for treating psychosis associated with interferon-alpha therapy |
| 08/26/2004 | WO2004002430A3 Combinations for the treatment of fungal infections |
| 08/26/2004 | WO2003101402A3 Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| 08/26/2004 | WO2003094965A8 Modulation of neural stem cells with s1p or lpa receptor agonists |
| 08/26/2004 | WO2003090681A3 SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
| 08/26/2004 | WO2003088905A3 Compositions and minimally invasive methods for treating incomplete tissue repair |
| 08/26/2004 | WO2003086283A3 Metastasis modulating activity of highly sulfated oligosaccharides |
| 08/26/2004 | WO2003079976A3 A substance with sedative effect |
| 08/26/2004 | WO2003070911A3 Rna interference mediated inhibition of type 1 insulin-like growth factor receptor (igf-1r) |
| 08/26/2004 | WO2003070823A3 Conjugates comprising a biodegradable polymer and uses therefor |
| 08/26/2004 | WO2003045354A8 Micropherules containing a pleuromutilin derivative |
| 08/26/2004 | WO2003026567A3 Use of neuraminidase inhibitors to prevent flu associated bacterial infections |
| 08/26/2004 | WO2002044334A3 Recombinant rsv virus expression systems and vaccines |
| 08/26/2004 | WO2001051003A3 Use of lipid conjugates in the treatment of disease |
| 08/26/2004 | US20040167572 Coated medical devices |
| 08/26/2004 | US20040167520 Spinous process implant with tethers |
| 08/26/2004 | US20040167358 Method and reagents for N-alkylating ureides |
| 08/26/2004 | US20040167352 Clarifying by centrifugation or filtration; adsorption on nonionic resin; adsorption efficiency greatly increased in strong basicity of ph 10 to 13 |
| 08/26/2004 | US20040167341 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 08/26/2004 | US20040167336 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine |
| 08/26/2004 | US20040167335 For therapy and prophylaxis of herpes viral infections |
| 08/26/2004 | US20040167334 Heterocyclic acylsulfimides, processes for their preparation, compositions comprising them and their use as pesticides |
| 08/26/2004 | US20040167332 Boronic ester and acid compounds, synthesis and uses |
| 08/26/2004 | US20040167330 Suitable targeting moieties are monoclonal antibodies, their fragments and recombinant derivatives such as single chain antibodies, diabodies, triabodies, humanized, human or chimeric variants but also peptides, aptamers, spiegelmers, nucleotides, anti sense oligomers |
| 08/26/2004 | US20040167323 Novel chitosans |